Pharmacokinetics of Transdermal Melatonin Products: A Randomized, Crossover Clinical Trial

Clicks: 6
ID: 333456
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #60 of 63 articles by views in SLEEP Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Study Objectives In some countries, melatonin is sold without a prescription and dosage is unregulated. This includes transdermal products without specific quantities of melatonin listed on the label. Our aim was to compare the pharmacokinetics of melatonin administered in oral, lotion, and bath product forms in a randomized, crossover clinical trial. Methods Melatonin levels in transdermal products were measured via HPLC and fluorescence. To determine pharmacokinetics, three different treatments (oral tablets, lotion, and bath immersion) were administered to twelve undergraduate participants in a random order. Five additional participants completed bath product treatment only. Participants collected saliva samples up to 48 hours after administration, which were analyzed for melatonin by enzyme-linked immunosorbent assay. Results Melatonin lotion products displayed lot-to-lot variability as well as changes in formulation and product claims; the lot used for this clinical trial contained 1.3 ± 0.05 mg melatonin/g lotion. Oral (n=11) and lotion treatments (n=12) caused maximum salivary melatonin levels within 30 minutes after administration, but bath immersion did not cause increases in saliva melatonin (n=17). The half-life of oral melatonin was 1.17 [0.69 – 1.65] hours versus 5.72 [3.75 – 7.68] hours for lotion treatment (p = 0.011, effect size r = 0.770). Conclusions Melatonin lotions contain undisclosed potent doses, are absorbed quickly, and remain at high physiological levels into the following day. This study is registered on clinicaltrials.gov (NCT06382610) and was funded by the Sleep Research Society and the National Heart, Lung, and Blood Institute of the National Institutes of Health Award Number R15HL179371.
Reference Key
openalex_W7223236617 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kathy Bonilla, Vanessa M Sherman, Alba S Arbaiza, Mason Dougherty, Lisa E. Olson
Are you one of these authors? Claim your profile
Journal SLEEP Advances
Year 2026
DOI
10.1093/sleepadvances/zpag115
URL
https://doi.org/10.1093/sleepadvances/zpag115
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.